menu
    • menu

    Company profile for Monte Rosa Therapeutics

    NEW Drugs in Dev: 4
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Every cell has evolved sophisticated machinery to regulate the expression and function of proteins by degradation. This elaborate mechanism involves the controlled ubiquitination of protein substrates by E3 ligase complexes. Using rationally designed small molecule degraders (also known as molecular glues) our goal is to hijack this natural process and redirect the degradation machinery to specific disease-causing proteins.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Monte Rosa TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    645 Summer Street Boston, MA 02135 United States
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.monterosatx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/monte-rosa-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASCO GU

    ASCO GU

    Not Confirmed

    envelop Contact Supplier

    ASCO GU

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Monte Rosa Therapeutics Presents at Upcoming Investor Conference
    Monte Rosa Therapeutics Presents at Upcoming Investor Conference

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/23/3242475/0/en/Monte-Rosa-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    Monte Rosa's MRT-8102 Delivers Profound CRP Reductions
    Monte Rosa's MRT-8102 Delivers Profound CRP Reductions

    07 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/07/3214388/0/en/Monte-Rosa-Therapeutics-Announces-Positive-Interim-Phase-1-Data-of-MRT-8102-Demonstrating-Profound-CRP-Reductions-in-Elevated-CVD-risk-Subjects.html

    GLOBENEWSWIRE
    07 Jan 2026
    Share Share
    Monte Rosa Therapeutics Plans Public Stock Offering
    Monte Rosa Therapeutics Plans Public Stock Offering

    07 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/07/3214890/0/en/Monte-Rosa-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html

    GLOBENEWSWIRE
    07 Jan 2026
    Share Share
    Monte Rosa Shares Interim Phase 1 Data for MRT-8102
    Monte Rosa Shares Interim Phase 1 Data for MRT-8102

    06 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/06/3214125/0/en/Monte-Rosa-Therapeutics-to-Present-Interim-MRT-8102-Phase-1-Study-Results.html

    GLOBENEWSWIRE
    06 Jan 2026
    Share Share
    Monte Rosa Therapeutics Reports Strong Clinical Response
    Monte Rosa Therapeutics Reports Strong Clinical Response

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/16/3206099/0/en/Monte-Rosa-Therapeutics-Announces-Compelling-Clinical-Activity-of-MRT-2359-in-Combination-with-Enzalutamide-in-Heavily-Pretreated-Metastatic-Castration-Resistant-Prostate-Cancer-Pa.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share
    Monte Rosa Therapeutics To Unveil Latest MRT-2359 Study Results
    Monte Rosa Therapeutics To Unveil Latest MRT-2359 Study Results

    15 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/15/3205830/0/en/Monte-Rosa-Therapeutics-to-Present-Updated-MRT-2359-Phase-1-2-Study-Results.html

    GLOBENEWSWIRE
    15 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search